SciSparc

About:

SciSparc is a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments.

Website: https://investor.scisparc.com

Description:

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.

Total Funding Amount:

$24.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Giv'atayim, Tel Aviv, Israel

Founded Date:

2014-01-01

Contact Email:

info(AT)therapixbio.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2023-10-11

IPO Status:

Public

Industries:

© 2025 bioDAO.ai